000 | 03259nam a22005295i 4500 | ||
---|---|---|---|
001 | 978-3-319-67932-7 | ||
003 | DE-He213 | ||
005 | 20210201191422.0 | ||
007 | cr nn 008mamaa | ||
008 | 180328s2018 gw | s |||| 0|eng d | ||
020 |
_a9783319679327 _9978-3-319-67932-7 |
||
050 | 4 | _aRC261-271 | |
072 | 7 |
_aMJCL _2bicssc |
|
072 | 7 |
_aMED062000 _2bisacsh |
|
072 | 7 |
_aMJCL _2thema |
|
082 | 0 | 4 |
_a614.5999 _223 |
245 | 1 | 0 |
_aResistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways _h[electronic resource] / _cedited by Yosef Yarden, Moshe Elkabets. |
250 | _a1st ed. 2018. | ||
264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2018. |
|
300 |
_aXX, 242 p. 22 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v15 |
|
500 | _aAcceso multiusuario | ||
505 | 0 | _aResistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis. | |
520 | _aThis volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance. | ||
541 |
_fUABC ; _cTemporal ; _d01/01/2021-12/31/2023. |
||
650 | 0 | _aCancer research. | |
650 | 1 | 4 |
_aCancer Research. _0https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
700 | 1 |
_aYarden, Yosef. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
700 | 1 |
_aElkabets, Moshe. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer Nature eBook | |
776 | 0 | 8 |
_iPrinted edition: _z9783319679303 |
776 | 0 | 8 |
_iPrinted edition: _z9783319679310 |
776 | 0 | 8 |
_iPrinted edition: _z9783030098179 |
830 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v15 |
|
856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-67932-7 |
912 | _aZDB-2-SBL | ||
912 | _aZDB-2-SXB | ||
942 | _cLIBRO_ELEC | ||
999 |
_c243266 _d243265 |